Phillip Md Et Al Frost Acquires 100,000 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 100,000 shares of the company’s stock in a transaction dated Tuesday, April 1st. The shares were purchased at an average cost of $1.65 per share, for a total transaction of $165,000.00. Following the transaction, the chief executive officer now directly owns 213,751,448 shares in the company, valued at approximately $352,689,889.20. The trade was a 0.05 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, March 28th, Phillip Md Et Al Frost acquired 150,000 shares of OPKO Health stock. The stock was acquired at an average price of $1.70 per share, for a total transaction of $255,000.00.
• On Monday, March 17th, Phillip Md Et Al Frost bought 200,000 shares of OPKO Health stock. The stock was acquired at an average cost of $1.74 per share, with a total value of $348,000.00.
• On Friday, February 28th, Phillip Md Et Al Frost acquired 67,434 shares of OPKO Health stock. The shares were bought at an average cost of $1.71 per share, for a total transaction of $115,312.14.
• On Tuesday, January 28th, Phillip Md Et Al Frost purchased 47,537 shares of OPKO Health stock. The stock was bought at an average price of $1.47 per share, with a total value of $69,879.39.
• On Friday, January 17th, Phillip Md Et Al Frost bought 150,000 shares of OPKO Health stock. The shares were acquired at an average cost of $1.47 per share, for a total transaction of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.48 per share, with a total value of $740,000.00.

OPKO Health Price Performance

OPK remained flat at $1.66 on Tuesday. 2,570,780 shares of the company were exchanged, compared to its average volume of 4,111,408. The business has a 50-day moving average price of $1.69 and a 200 day moving average price of $1.58. OPKO Health, Inc. has a 52-week low of $1.15 and a 52-week high of $2.04. The stock has a market cap of $1.11 billion, a P/E ratio of -8.74 and a beta of 1.70. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The firm had revenue of $183.60 million for the quarter, compared to analysts’ expectations of $155.42 million. As a group, equities research analysts forecast that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on OPK. HC Wainwright restated a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a report on Wednesday, March 19th. Barrington Research reaffirmed an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a report on Wednesday, March 12th. Finally, StockNews.com upgraded OPKO Health from a “sell” rating to a “hold” rating in a research report on Monday, March 3rd.

Institutional Investors Weigh In On OPKO Health

A number of hedge funds and other institutional investors have recently bought and sold shares of OPK. Intech Investment Management LLC acquired a new position in shares of OPKO Health in the third quarter valued at $190,000. FMR LLC increased its position in OPKO Health by 103.6% during the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares in the last quarter. BNP Paribas Financial Markets increased its position in OPKO Health by 736.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock valued at $368,000 after acquiring an additional 217,450 shares during the period. Verition Fund Management LLC bought a new position in OPKO Health during the 3rd quarter worth approximately $201,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in OPKO Health during the third quarter worth approximately $138,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.